Initial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women
Clarus is seeking Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in the second quarter of 2022
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Initial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women
Clarus is seeking Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in the second quarter of 2022
Read more at globenewswire.com